Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, please visit www.lantheus.com.
Location: United States, Massachusetts, Billerica
Employees: 501-1000
Founded date: 1956
Investors 1
| Date | Name | Website |
| - | Avista Cap... | avistacap.... |
Mentions in press and media 22
| Date | Title | Description |
| 09.12.2025 | The Frost & Sullivan Institute Honors Global Organizations Advancing Sustainable Progress with the 2025 Visionary Growth Leadership Best Practices Recognition | SANTA CLARA, Calif., Dec. 9, 2025 /PRNewswire/ -- The Frost & Sullivan Institute is pleased to announce the recipients of the 2025 Visionary Growth Leadership Best Practices Recognition. This honor celebrates organizations that are rede... |
| 28.01.2025 | Lantheus to Acquire Evergreen Theragnostics to Expand Radiopharmaceutical Capabilities | What You Should Know: – Lantheus Holdings, Inc., a radiopharmaceutical company, announced today a definitive agreement to acquire Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company. – The all-cash transaction consis... |
| 12.03.2024 | Appointment of Dr Darren Patti to Group Chief Operating Officer | MELBOURNE, Australia, March 12, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024. Dr... |
| 11.03.2024 | Appointment of Dr Darren Patti to Group Chief Operating Officer | MELBOURNE, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024... |
| 05.03.2024 | Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024 | - |
| 08.02.2023 | Lantheus Announces Acquisition of Cerveau Technologies, Expanding Imaging Pipeline into Alzheimer’s Disease | MK-6240 is an F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s Disease Lantheus Holdings, a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions t... |
| 24.02.2022 | Palette Life Sciences inleder ett samarbete med Lantheus för att marknadsföra PYLARIFY® (piflufolastat F-18) | SANTA BARBARA, Calif. och STOCKHOLM, Sverige, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences (”Palette”), ett globalt företag inom medicinteknik som arbetar för att förbättra behandlingsresultaten av bland annat strålbehandling av ... |
| 24.02.2022 | Palette Life Sciences Enters Into an Agreement with Lantheus to Support the Promotion of PYLARIFY® (Piflufolastat F18) | Partnership leverages Palette’s specialty sales team to increase promotional footprint of PYLARIFY within the urology call point SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences (“Palette”... |
| 06.12.2021 | Lantheus Announces PYLARIFY AI is Now Available | Lantheus Holdings, Inc., an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, anno... |
| 14.06.2017 | Lantheus Holdings, Inc. Announces Public Secondary Offering by Selling Stockholders of 3,000,000 Shares of Common Stock | North Billerica, MA, June 14 2017 – (Business Wire) – Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ:LNTH), today announced an agreement to sell 3,000,000 shares of its common stock to be offered by certain of its existing st... |
Show more